Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
about
Dimethyl fumarate for multiple sclerosisDimethyl fumarate for multiple sclerosisThe potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospectsMultiple sclerosis-a quiet revolutionNew and emerging immune-targeted drugs for the treatment of multiple sclerosisPathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysMechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid estersThe clinical potential of influencing Nrf2 signaling in degenerative and immunological disordersThe effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyUse of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin AmericaTime course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosisPre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.Drugs in development for relapsing multiple sclerosis.The fumaric acid ester BG-12: a new option in MS therapy.Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J MeDimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.Novel immunomodulatory approaches for the management of multiple sclerosis.Established and novel disease-modifying treatments in multiple sclerosis.Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
P2860
Q24186433-BAEBB99F-28BE-481F-9827-0E929954D3BAQ24197602-B8E36680-B2A8-4466-A3FB-1FC2BE48160EQ26770815-88C94754-7003-4562-8B73-94354680E371Q26826930-8312BE1F-7BEE-4E15-AC5F-6C36108B3718Q26997067-E32B1299-B205-4472-8ADA-C748C24C83EBQ28235168-DC1DC069-31AA-427D-8DAF-EA307FB2734DQ28389828-F938E438-C7A1-4836-A137-98527CCDF451Q28395641-A2671215-DBE6-4A47-95F0-F197BF24BCB8Q33621682-9CDA5EF1-2648-426F-9831-3AB89D92B313Q34136565-DF5116BD-A048-47A6-B55C-302ACCB38EC1Q34667496-5DDBC30B-F2F3-4944-9E4A-F5CB8CEFD19DQ35211079-6A8F40B3-94DA-4E28-AAB4-FEE042AC6AC4Q35907969-6F8C3A6E-D39B-4035-AF30-9DF040C3BFA6Q36361543-49024590-7B80-4BD4-9074-1A18B7A0A20BQ36613394-FBE08B2C-4B2C-4385-86FB-DCA5384E2A22Q38083041-2A4B8256-338A-40CC-847C-2073221DDFE6Q38101004-EC29D385-6460-43CD-9B59-E4D3DEA75E1DQ38128863-CC67106E-DAD1-4C14-A763-FE010BBD188AQ38131058-95AA7904-9CDB-4862-8949-8A9E1A0F1027Q38141840-2377C3BF-8DC4-43AC-BD09-8771DBE74EA5Q38156608-E5A2E976-BBA7-4021-A2FD-839A57B9B9CEQ38180157-E3C369E2-382C-4766-98F2-3BFCACD6D74AQ38753455-09E9B1B7-F4EA-46E1-A8F9-659D301756DDQ44787272-C5CDA8D6-3D95-4C96-98C4-3A1244B4E225Q46760321-3522A45D-E6E2-4EB8-818F-DBAF78C1E55AQ53326795-44F9EA87-27BF-4321-9336-6D2E4833368BQ58805531-A6594BE0-114A-430A-A7A1-CDA50F01A421
P2860
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@ast
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@en
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@nl
type
label
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@ast
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@en
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@nl
prefLabel
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@ast
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@en
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@nl
P2093
P2860
P921
P356
P1476
Effect of BG-12 on contrast-en ...... lyses from the phase 2b study.
@en
P2093
Chris H Polman
David G MacManus
David H Miller
Eva Havrdova
Eva Meluzinova
Gilmore N O'Neill
Kate Dawson
Klaus Schmierer
Mefkure Eraksoy
Michal Dufek
P2860
P304
P356
10.1177/1352458511421054
P577
2011-08-30T00:00:00Z